title: Effects of anti-endothelial cell antibody in pre-eclampsia on endothelin-1 release from cultured endothelial cells.
abstract: In order to investigate the pathophysiological significance of anti-endothelial cell antibody (AECA) in pre-eclampsia, the effects of AECA on endothelin-1 (ET-1) and prostaglandin I2 (PGI2) release from cultured human umbilical vein endothelial cells (HUVEC) was evaluated. Serum samples were taken from 85 pre-eclamptic and 20 normal pregnant women. Anti-endothelial cell antibody was measured by ELISA using HUVEC. The release of ET-1 and 6-keto PGF1-alpha, a stable metabolite of PGI2, from HUVEC were evaluated after incubation with IgG-AECA-positive sera and IgG isolated from AECA-positive sera. The incidence of IgG- and IgM-AECA was 24.7 and 8.2%, respectively. The release of ET-1, in the medium containing IgG-AECA-positive sera was significantly greater than in the medium containing IgG-AECA-negative sera. There was significant correlation between the levels of IgG-AECA and the release of ET-1 from endothelial cells. The ET-1 release by IgG isolated from AECA-positive sera was greater than that from AECA-negative sera. However, the release of 6-keto PGF1-alpha by AECA-positive sera was not significantly different from that of AECA-negative sera. It is concluded that IgG-AECA in pre-eclampsia increases ET-1 release from endothelial cells and that AECA may affect local vascular function in this disorder.
authors.affiliation: Department of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Takahashi
authors.forename: S
authors.initials: S
authors.lastname: Kuno
authors.forename: Y
authors.initials: Y
authors.lastname: Geshi
authors.forename: Y
authors.initials: Y
authors.lastname: Sasamori
authors.forename: H
authors.initials: H
authors.lastname: Mori
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D001323:Autoantibodies / Q000097:blood* / Q000494:pharmacology; D002478:Cells, Cultured; D004306:Dose-Response Relationship, Immunologic; D019332:Endothelin-1 / Q000378:metabolism*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology; D007375:Interleukin-1 / Q000097:blood; D011225:Pre-Eclampsia / Q000276:immunology*; D011247:Pregnancy; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
chemical_list: D001323:Autoantibodies; D019332:Endothelin-1; D007074:Immunoglobulin G; D007375:Interleukin-1; D016212:Transforming Growth Factor beta; D014409:Tumor Necrosis Factor-alpha; C087589:anti-endothelial cell antibody; D015121:6-Ketoprostaglandin F1 alpha